{"id":"triamcinolone-optional","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Adrenal suppression"},{"rate":null,"effect":"Skin atrophy (topical use)"},{"rate":null,"effect":"Mood changes / psychiatric effects"}]},"_chembl":{"chemblId":"CHEMBL1200449","moleculeType":"Small molecule","molecularWeight":"478.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triamcinolone exerts its anti-inflammatory and immunosuppressive effects by binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and migration, and suppression of inflammatory mediators. It is used topically, intramuscularly, intra-articularly, or systemically depending on the indication.","oneSentence":"Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:24.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)"},{"name":"Rheumatoid arthritis and other joint disorders"},{"name":"Respiratory conditions (asthma, COPD)"},{"name":"Adrenocortical insufficiency"},{"name":"Systemic lupus erythematosus and other autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":"Post Cataract Surgery","enrollment":40},{"nctId":"NCT02576938","phase":"PHASE2","title":"A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-02","conditions":"Atopic Dermatitis","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["clobetasol"],"phase":"marketed","status":"active","brandName":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions (dermatitis, eczema, psoriasis), Rheumatoid arthritis and other joint disorders, Respiratory conditions (asthma, COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}